Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that can block the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential to be used in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902) for research on colorectal cancer (CRC). This evidence concerns the gene CD274 and colorectal carcinoma.